You searched for clinical trials - Page 17 of 44

ASH 2021: Dr. Jake Soumerai on Measurable Residual Disease-Guided Treatment of Chronic Lymphocytic Leukemia (CLL) with Venetoclax and Obinutuzumab plus Zanubrutinib

September 13, 2022

At the American Society of Hematology (ASH) 2021, our own Dr. Brian Koffman interviewed Dr. Jake Soumerai, a clinical investigator at Massachusetts General Hospital and an Assistant Professor at Harvard Medical School. They discussed MRD as a biomarker to direct treatment duration in a phase 2 clinical trial of triple combination venetoclax and obinutuzumab plus zanubrutinib.

ASH 2021: Dr. Anthony Mato on Updated Results from the BRUIN Study of Non-Covalent BTK Inhibitor Pirtobrutinib

September 13, 2022

We discuss updated results from the BRUIN study, a phase 1/2 clinical trial of pirtobrutinib in patients with advanced B-cell malignancies, including CLL, who have received >2 prior therapies.

Elisabeth Wright Shares Her Journey with CLL

August 26, 2022

Eight years ago this month, I was diagnosed with chronic lymphocytic leukemia (CLL). My world turned upside down. I knew nothing about CLL but had to get smart on the subject. And I did this with the help of good doctors and organizations such as the CLL Society.

Announcing the Winner of CLL Society’s First Ever Young Investigator Research Program Award: Dr. Christine Ryan on the Topic of Richter’s Syndrome

August 19, 2022

In January 2022, CLL Society formally announced the launch of a new Research Program that is devoted to supporting underfunded areas of bench and translational science to make progress in the following four critical areas of unmet needs for those diagnosed with CLL / SLL:

ASH 2021: Dr. Megan Thompson on Outcomes of Subsequent Therapies after Exposure to Bruton’s Tyrosine Kinase Inhibitors and Venetoclax

July 27, 2022

We discuss results from two new studies, which looked at real-world outcomes of subsequent therapies in patients whose disease progressed after either 1) double-exposure to a covalent BTK inhibitor and venetoclax or 2) exposure to a non-covalent BTK inhibitor.

ASH 2021 – Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) After Progression on I Alone (V-naïve) or After Progression on Sequential I and V (Double Refractory)

July 13, 2022

Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) After Progression on I Alone (V-naïve) or after Progression on Sequential I and V (Double Refractory)

ASH 2021: Trial in Progress: Phase 1b Study of Lisaftoclax (APG-2575) As a Single Agent or Combined with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (R/R CLL / SLL)

July 13, 2022

Dr. Matthew Davids and colleagues presented this research at the American Society for Hematology annual meeting held in December 2021 (ASH 2021).

ASH 2021: Dr. Alex Herrera on Atezolizumab in Combination with Immunogenic Chemotherapy for Aggressive B-Cell Lymphomas

July 6, 2022

Discussion of new results from a phase 1 clinical trial of the atezolizumab plus immunogenic chemotherapy. Atezolizumab is a checkpoint inhibitor that blocks PD-L1, a checkpoint protein found on cancer cells. It is already approved for use in treating certain types of bladder cancers and lung cancers.

FDA Warns About Possible Increased Risk of Death and Serious Side Effects with Cancer Drug Copiktra (Duvelisib)

July 1, 2022

The days may be numbered for the use of duvelisib, a very effective but potentially toxic oral medication used in CLL / SLL.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Search Results for: clinical trials – Page 17

ASH 2021: Dr. Jake Soumerai on Measurable Residual Disease-Guided Treatment of Chronic Lymphocytic Leukemia (CLL) with Venetoclax and Obinutuzumab plus Zanubrutinib

ASH 2021: Dr. Anthony Mato on Updated Results from the BRUIN Study of Non-Covalent BTK Inhibitor Pirtobrutinib

Elisabeth Wright Shares Her Journey with CLL

Announcing the Winner of CLL Society’s First Ever Young Investigator Research Program Award: Dr. Christine Ryan on the Topic of Richter’s Syndrome

ASH 2021: Dr. Megan Thompson on Outcomes of Subsequent Therapies after Exposure to Bruton’s Tyrosine Kinase Inhibitors and Venetoclax

ASH 2021 – Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) After Progression on I Alone (V-naïve) or After Progression on Sequential I and V (Double Refractory)

ASH 2021: Trial in Progress: Phase 1b Study of Lisaftoclax (APG-2575) As a Single Agent or Combined with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (R/R CLL / SLL)

ASH 2021: Dr. Alex Herrera on Atezolizumab in Combination with Immunogenic Chemotherapy for Aggressive B-Cell Lymphomas

FDA Warns About Possible Increased Risk of Death and Serious Side Effects with Cancer Drug Copiktra (Duvelisib)

Didn't find what you where looking for?

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT